Related Experiment Video
Updated: Jun 16, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Hypofractionated radiotherapy has the potential for second cancer reduction.
Uwe Schneider1, Jürgen Besserer, Andreas Mack
1Radiotherapy Hirslanden AG, Institute for Radiotherapy, Rain 34, Aarau, Switzerland. uschneider@vetclinics.uzh.ch
Theoretical Biology & Medical Modelling
|February 13, 2010
Summary
Increasing radiation therapy fraction size may reduce second cancer risks, particularly for sarcoma. Larger dose fractions appear beneficial for lowering the incidence of secondary carcinomas and sarcomas after radiotherapy.
Area of Science:
- Radiation oncology
- Cancer research
- Radiobiology
Background:
- Radiotherapy is a cornerstone of cancer treatment.
- Understanding factors influencing secondary cancer induction is crucial for optimizing treatment strategies.
Purpose of the Study:
- To investigate the relationship between radiotherapy fractionation and the induction of secondary carcinomas and sarcomas.
- To determine the impact of dose per fraction on carcinogenesis risk.
Main Methods:
- Utilized a cancer induction model to simulate carcinoma and sarcoma development after radiation therapy.
- Analyzed dose-response relationships across various fractionation schemes.
- Examined tumor induction as a function of radiation dose per fraction.
Main Results:
- Larger fraction sizes were associated with decreased second cancer induction when assuming the same biologically equivalent dose.
- Carcinoma risk decreased by approximately 10% per 1 Gy increase in fraction dose.
- Sarcoma risk showed a more pronounced decrease, around 15% per 1 Gy increase in fraction dose.
- Irradiating tissues to lower dose levels with large fractions potentially reduced sarcoma development compared to irradiation across all dose levels.
Conclusions:
- Increasing the dose per fraction (hypofractionation) reduces both carcinoma and sarcoma induction risk.
- The reduction in sarcoma risk is more significant than that for carcinoma.
- Hypofractionation may be a beneficial strategy for minimizing the risk of secondary cancers post-radiotherapy.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...